Investigational Drug Information for Gefapixant
✉ Email this page to a colleague
What is the development status for investigational drug Gefapixant?
Gefapixant is an investigational drug.
There have been 27 clinical trials for Gefapixant.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 15th 2018.
The most common disease conditions in clinical trials are Cough, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are Afferent Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., and Celerion.
There are seventeen US patents protecting this investigational drug and one hundred and eighty-one international patents.
Summary for Gefapixant
| US Patents | 17 |
| International Patents | 181 |
| US Patent Applications | 73 |
| WIPO Patent Applications | 31 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 3 (2018-03-15) |
| Vendors | 47 |
Recent Clinical Trials for Gefapixant
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough | Melbourne Health | Early Phase 1 |
| Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough | Merck Sharp & Dohme LLC | Early Phase 1 |
| Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough | Monash University | Early Phase 1 |
Clinical Trial Summary for Gefapixant
Top disease conditions for Gefapixant
Top clinical trial sponsors for Gefapixant
US Patents for Gefapixant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gefapixant | ⤷ Sign Up | Methods and compositions for treating diseases and conditions | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | ⤷ Sign Up |
| Gefapixant | ⤷ Sign Up | Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | ⤷ Sign Up |
| Gefapixant | ⤷ Sign Up | Methods and compositions for treating diseases and conditions | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | ⤷ Sign Up |
| Gefapixant | ⤷ Sign Up | Crystalline salts and polymorphs of a P2X3 antagonist | Afferent Pharmaceuticals, Inc. (San Mateo, CA) | ⤷ Sign Up |
| Gefapixant | ⤷ Sign Up | 5 to 7 membered heterocyclic amides as JAK inhibitors | Theravance Biopharma R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| Gefapixant | ⤷ Sign Up | Diaminopyrimidines as P2X.sub.3 and P2X.sub.2/3 antagonists | Roche Palo Alto LLC (Palo Alto, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gefapixant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gefapixant | European Patent Office | EP3164132 | 2034-07-03 | ⤷ Sign Up |
| Gefapixant | European Patent Office | EP3981406 | 2034-07-03 | ⤷ Sign Up |
| Gefapixant | World Intellectual Property Organization (WIPO) | WO2016004358 | 2034-07-03 | ⤷ Sign Up |
| Gefapixant | Australia | AU2014308606 | 2033-08-23 | ⤷ Sign Up |
| Gefapixant | Canada | CA2921395 | 2033-08-23 | ⤷ Sign Up |
| Gefapixant | Chile | CL2016000400 | 2033-08-23 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
